ID   A2780/CP20
AC   CVCL_A5PS
SY   A2780(CP20); A2780-CP-20; A2780CP20
DR   cancercelllines; CVCL_A5PS
DR   IARC_TP53; 5551
DR   Wikidata; Q107113315
RX   PubMed=3539322;
RX   PubMed=8557231;
CC   Population: African American.
CC   Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP).
CC   Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Pro604Ser (c.1810C>T); ClinVar=VCV000127343; Zygosity=Unspecified (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys128_Arg130del (c.383_391del9); Zygosity=Unspecified (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val173Phe (c.517G>T); Zygosity=Unspecified (PubMed=8557231).
CC   Derived from site: In situ; Ovary; UBERON=UBERON_0000992.
DI   NCIt; C7979; Ovarian endometrioid adenocarcinoma
DI   ORDO; Orphanet_454723; Endometrioid carcinoma of ovary
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0134 ! A2780
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 20-05-21; Last updated: 05-10-23; Version: 5
//
RX   PubMed=3539322;
RA   Behrens B.C., Hamilton T.C., Masuda H., Grotzinger K.R.,
RA   Whang-Peng J., Louie K.G., Knutsen T., McKoy W.M., Young R.C.,
RA   Ozols R.F.;
RT   "Characterization of a cis-diamminedichloroplatinum(II)-resistant
RT   human ovarian cancer cell line and its use in evaluation of platinum
RT   analogues.";
RL   Cancer Res. 47:414-418(1987).
//
RX   PubMed=8557231; DOI=10.1006/gyno.1996.0014;
RA   Skilling J.S., Squatrito R.C., Connor J.P., Niemann T., Buller R.E.;
RT   "p53 gene mutation analysis and antisense-mediated growth inhibition
RT   of human ovarian carcinoma cell lines.";
RL   Gynecol. Oncol. 60:72-80(1996).
//